AC Immune SA, PSE Building B, Swiss Federal Institute of Technology Lausanne (EPFL), CH-1015 Lausanne, Switzerland.
J Biol Chem. 2012 Oct 5;287(41):34786-800. doi: 10.1074/jbc.M112.357665. Epub 2012 Aug 13.
Increasing evidence implicates Aβ peptides self-assembly and fibril formation as crucial events in the pathogenesis of Alzheimer disease. Thus, inhibiting Aβ aggregation, among others, has emerged as a potential therapeutic intervention for this disorder. Herein, we employed 3-aminopyrazole as a key fragment in our design of non-dye compounds capable of interacting with Aβ42 via a donor-acceptor-donor hydrogen bond pattern complementary to that of the β-sheet conformation of Aβ42. The initial design of the compounds was based on connecting two 3-aminopyrazole moieties via a linker to identify suitable scaffold molecules. Additional aryl substitutions on the two 3-aminopyrazole moieties were also explored to enhance π-π stacking/hydrophobic interactions with amino acids of Aβ42. The efficacy of these compounds on inhibiting Aβ fibril formation and toxicity in vitro was assessed using a combination of biophysical techniques and viability assays. Using structure activity relationship data from the in vitro assays, we identified compounds capable of preventing pathological self-assembly of Aβ42 leading to decreased cell toxicity.
越来越多的证据表明,β淀粉样肽的自组装和纤维形成是阿尔茨海默病发病机制中的关键事件。因此,抑制 Aβ 聚集等,已成为治疗这种疾病的一种潜在治疗干预手段。在此,我们以 3-氨基吡唑为关键片段,设计了非染料化合物,这些化合物能够通过与 Aβ42 的供体-受体-供体氢键模式相互作用,与 Aβ42 的β-折叠构象互补,从而与 Aβ42 相互作用。化合物的初始设计基于通过连接体将两个 3-氨基吡唑部分连接起来,以确定合适的支架分子。还探索了两个 3-氨基吡唑部分上的额外芳基取代,以增强与 Aβ42 氨基酸的π-π 堆积/疏水相互作用。使用多种生物物理技术和活力测定法,评估了这些化合物在体外抑制 Aβ 纤维形成和毒性的功效。根据体外测定的构效关系数据,我们鉴定出了能够预防 Aβ42 病理性自组装从而降低细胞毒性的化合物。